The role of nonsteroidal antiinflammatory drugs in cancer chemoprevention

Drugs of the Future

Volumn 29, Issue 5, 2004, Pages 467-478

  Young, Charles Y F ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN RECEPTOR; BETA CATENIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EARLY GROWTH RESPONSE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E2; ROFECOXIB; SULINDAC SULFIDE; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 4; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOASSAY; BIOAVAILABILITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; DRUG ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; MALIGNANT TRANSFORMATION; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

EID: 3242884127     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.05.851323     Document Type: Review

References (158)

1. Tarnawski, A.S., Jones, M.K. Inhibition of angiogenesis by NSAIDs: Molecular mechanisms and clinical implications. J Mol Med 2003, 81: 627-36.
2. Davies, G.L.S. Cyclooxygenase-2 and chemoprevention of breast cancer. J Steroid Biochem Mol Biol 2003, 86: 495-9.
3. Bakhle, Y.S. COX-2 and cancer: A new approach to an old problem. Brit J Pharmacol 2001, 134: 1137-50.
4. Hawk, E.T., Viner, J.L., Dannenberg, A., DuBois, R.N. COX-2 in cancer - A player that's defining the rules. J Natl Cancer Inst 2002, 94: 545-6.
5. Majima, M., Amano, H., Hayashi, I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003, 24: 524-9.
6. Rao, M., Yang, W., Seifalian, A.M, Winslet, M.C. Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Intl J Colorectal Dis 2004, 19: 1-11.
7. Jolly, K., Cheng, K.K., Langman, M.J.S. NSAIDs and gastrointestinal cancer prevention. Drugs 2002, 62: 945-56.
8. Romano, M., Claria, J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. FASEB J 2003, 17: 1986-95.
9. Corley, D.A., Kerlikowske, K., Verma, R., Buffler, P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003, 124: 47-56.
10. Harris, R.E., Chlebowski, R.T., Jackson, R.D., Frid, D.J., Ascenseo, J.L., Anderson, G., Loar, A., Rodabough, R.J., White, E., McTiernan, A. Breast cancer and nonsteroidal anti-inflammatory drugs: Prospective results from the women's health initiative. Cancer Res 2003, 63: 6096-101.
11. Levy, G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 1997, 11: 234-47.
12. Vainio, H. Is COX-2 inhibition a panacea for cancer prevention? Intl J Cancer 2001, 94: 613-4.
13. Khuder, S.A., Mutgi, A.B. Breast cancer and NSAID use: A meta-analysis. Brit J Cancer 2001, 84: 1188-92.
14. Husain, S.S., Szabo, I.L., Tarnawski, A.S. NSAID inhibition of GI cancer growth: Clinical implications and molecular mechanisms of action. Am J Gastroenterol 2002, 97: 542-53.
15. Bucher, C., Jordan, P., Nickeleit, V., Torhorst, J., Mihatsch, M.J. Relative risk of malignant tumors in analgesic abusers: Effects of long-term intake of aspirin. Clin Nephrol 1999, 51: 67-72.
16. Goluboff, E.T., Shabsigh, A., Saidi, J.A., Weinstein, I.B., Mitra, N., Heitjan, D., Piazza, G.A., Pamukcu, R., Buttyan, R., Olsson, C.A. Exsulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 1999, 53: 440-5
17. Myers, C., Koki, A., Pamukcu, R., Wechter, W., Padley, R.J. Proapoptotic anti-inflammatory drugs. Urology 2001, 57(4a, Suppl. S): 73-6.
18. Roberts, R.O., Jacobson, D.J., Girman, C.J., Rhodes, T., Lieber, M.M., Jacobsen, S.J. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clinic Proc 2002, 77: 219-25.
19. Norrish, A.E, Jackson, R.T, McRae, C.U. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Intl J Cancer 1998, 77: 511-5.
20. Paganini-Hill, A, Chao, A, Ross, R.K, Henderson, B.E. Aspirin use and chronic diseases: A cohort study of the elderly. Brit Med J (BMJ) 1989, 299: 1247-50.
21. Nelson, J.E., Harris, R.E. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study. Oncol Rep 2000, 7: 169-70.
22. Chandrasekharan, N.V., Dai, H., Roos, K.L.T., Evanson, N.K., Tomsik, J., Elton, T.S., Simmons, D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002, 99: 13926-31.
23. Schwab, J.M., Schluesener, H.J., Meyermann, R., Serhan, C.N. COX-3 the enzyme and the concept: Steps towards highly specialized pathways and precision therapeutics? Prostagland Leuk Essent Fatty Acids 2003, 69: 339-43.
24. Simmons, D.L. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 2003, 110: 265-8.
25. 2, phosphatidyllnositol-specific phospholipase C activities and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F34 rats. Cancer Res 1996, 56: 532-7.
26. Eberhart, C.E., Coffey, R.J., Radhika, A., Giardello, F.M., Ferrenbach, S., DuBois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107: 1183-8.
27. Kutchera, W., Jones, D., Matsumani, N., Groden, J., McIntyre, T.M., Zimmerman, G.A., White, R.L., Prescott, S.M. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: Evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996, 93: 4816-20.
28. Muller-Decker, K., Albert, C., Lukanov, T., Winde, G., Marks, F., Furstenberger, G. Cellular localization of cyclooxygenase isozymes in Crohn's disease and colorectal cancer. Intl J Colorectal Dis 1999, 14: 212-8.
29. Gustafson-Svard, C., Lilja, I., Hallbook, O., Sjodahl, R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 1996, 38: 79-84.
30. DuBois, R.N., Shao, J., Tsujii, M., Sheng, H., Beauchamp, R.D G 1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996, 56: 733-7.
31. Sano, H., Kawahito, Y., Wilder, R.L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., Hla, T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 55: 3785-9.
32. Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., Kumar, R. Regulation of cyclooxygenase-2 pathway by HER-2 receptor. Oncogene 1999, 18: 305-14.
33. Murono, S., Inoue, H., Tanabe, T., Joab, I., Yoshizaki, T., Furukawa, M., Pagano, J.S. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001, 98: 6905-10.
34. Chulada, P.C., Thompson, M.B., Mahler, J.F., Doyle, C.M., Gaul, B.W., Lee, C., Tiano, H.F., Morham, S.G., Smithies, O., Langenbach, R. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60: 4705-8.
35. Takeda, H, Sonoshita, M., Oshima, H., Sugihara, K., Chulada, P.C., Langenbach, R., Oshima, M., Taketo, M.M. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 2003, 63: 4872-7.
36. Majima, M., Amano, H., Hayashi, I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 2003, 24: 524-9.
37. Oviedo, J.A., Wolfe, M.M. Gastroprotection by coxibs: What do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research trial tell us? Rheum Dis Clin North Am 2003, 29: 769.
38. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agarwal, N.M., Stenson, W.F., Burr, A.M., Zhao, W.W., Kent, J.D., Lefkowith, J.B., Verburg, K.M., Geis, G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial. JAMA - J Am Med Assoc 2000, 284: 1247-55.
39. Mukherjee, D., Nissen, S.E., Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA - J Am Med Assoc 2001, 286: 954-9.
40. Schernhammer, E.S., Kang, J.H., Chan, A.T., Michaud, D.S., Skinner, H.G., Giovannucci, E., Colditz, G.A., Fuchs, C.S. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 2004, 96: 22-8.
41. Baron, J.A. What now for aspirin and cancer prevention? J Natl Cancer Inst 2004, 96: 4-5.
42. Anderson, K.E., Johnson, T.W., Lazovich, D., Folsom, A.R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002, 94: 1168-71.
43. Kokawa, A., Kondo, H., Gotoda, T., Ono, H., Saito, D., Nakadaira, S., Kosuge, T., Yoshida, S. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001, 91: 333-8.
44. Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., Hasegawa, R., Imaida, K. et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990, 11: 393-5.
45. Jaiswal, M., LaRusso, N.F., Gores, G.J. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: Linking inflammation to oncogenesis. Am J Physiol - Gastrointest Liver Physiol 2001, 281: G626-34.
46. Torok, N.J., Higuchi, H., Bronk, S., Gores, G.J. Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9. Cancer Res 2002, 62: 1648-53.
47. 4 receptors. Intl J Cancer 2004, 108: 384-9.
48. Chan, T.A., Morin, P.J., Vogelstein, B., Kinzler, K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998, 95: 681-6.
49. Key, T.J., Pike, M.C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1998, 24: 29-43.
50. Thomas, H.V., Key, T.J., Allen, D.S., Moore, J.W., Dowsett, M., Fentiman, I.S., Wang, D.Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Brit J Cancer 1997, 76: 401-5.
51. Helzlsouer, K.J., Alberg, A.J., Bush, T.L., Longcope, C., Gordon, G.B., Comstock, G.W. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994, 18: 79-85.
52. Reed, M.J., Owen, A.M., Lai, L.C., Coldham, N.G., Ghilchik, M.W., Shaikh, N.A., James, V.H. In situ oestrone synthesis in normal breast and breast tumour tissues: Effect of treatment with 4-hydroxyandrostenedione. Intl J Cancer 1989, 44: 233-7.
53. O'Neill, J.S., Elton, R.A., Miller, W.R. Aromatase activity in adipose tissue from breast quadrants: A link with tumour site. Brit Med J (Clin Res Ed) 1988, 296: 741-3.
54. Zhou, C., Zhou, D., Esteban, J., Murai, J., Siiteri, P.K., Wilczynski, S., Chen, S. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 1996, 59: 163-71.
55. Mahendroo, M.S., Mendelson, C.R., Simpson, E.R. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J Biol Chem 1993, 268: 19463-70.
56. Michael, M.D., Michael, L.F., Simpson, E.R. A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene. Mol Cell Endocrinol 1997, 134: 147-56.
57. Zhao, Y., Agarwal, V.R., Mendelson, C.R., Simpson, E.R. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137: 5739-42.
58. Brueggemeier, R.W., Quinn, A.L., Parrett, M.L., Joarder, F.S., Harris, R.E., Robertson, F.M. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999, 140: 27-35.
59. Jones, M.K., Szabo, I.L., Kawanaka, H., Husain, S.S., Tarnawski, A.S. Von Hippel Lindau tumor suppressor and HIF-1-new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 2002, 16: 265-6
60. 2-regulated prolyl hydroxylation. Science 2001, 292: 468-72
61. 2 sensing. Science 2001, 292: 464-8.
62. Yu, F., White, S.B., Zhao, Q., Lee, F.S. HIF-1 binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001, 98: 9630-5.
63. Levy, A.P., Levy, N.S., Goldberg, M.A. Post-transcriptional regulation of vascular endothelial cell growth factor by hypoxia. J Biol Chem 1996, 271: 2746-53.
64. Gerber, H.J.P., Condorelli, F., Park, J., Ferrara, N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 1997, 272: 23659-67.
65. 2 tension. Proc Natl Acad Sci USA 1995, 92: 5510-4.
66. Pugh, C.W., Ratcliffe, P.J. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003, 9: 677-4
67. Tarnawski, A.S., Jones, M.K. Inhibition of angiogenesis by NSAIDs: Molecular mechanisms and clinical implications. J Mol Med 2003, 81: 627-36.
68. Nishi, H., Nishi, K.H., Johnson, AC. Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002, 62: 827-34.
69. Yan, S.F., Fujita, T., Lu, J., Okada, K, Shan Zou, Y., Mackman, N., Pinsky, D.J., Stern, D.M. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000, 6: 1355-61.
70. Stula, M., Orzechowski, H.D., Gschwend, S., Vetter, R., von Harsdorf, R., Dietz, R., Paul, M. Influence of sustained mechanical stress of Egr-1 mRNA expression in cultured human endothelial cells. Mol Cell Biochem 2000, 210: 101-8
71. Vidal, F., Aragones, J., Alfranca, A., de Landazuri, M.O. Upregulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: Role of transcription factor Egr-1. Blood 2000, 95: 3387-5.
72. Fahmy, R.G., Dass, C.R., Sun, L.Q., Chesterman, C.N., Khachigian, L.M. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 2003, 9: 1026-32.
73. Szabo, I.L, Pai, R., Soreghan, B., Jones, M.K., Baatar, D., Kawanaka, H., Tarnawski, A.S. NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis? J Physiol (Paris) 2001, 95: 379-83.
74. Boon, E.M., Keller, J.J., Wormhoudt, T.A., Giardiello, F.M., Offerhaus, G.J., van der Neut, R., Pals, S.T. Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Brit J Cancer 2004, 90: 224-9.
75. Brown, W.A., Skinner, S.A., Vogiagis, D., O'Brien, P.E. Inhibition of β-catenin translocation in rodent colorectal tumors - A novel explanation for the protective effect of nonsteroidal anti-inflammatory drugs in colorectal cancer. Digest Dis Sci 2001, 46: 2314-21.
76. Smith, M.L., Hawcroft, G., Hull, M.A. The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: Evidence of different mechanisms of action. Eur J Cancer 2000, 36: 664-74.
77. Dihlmann, S, Klein, S., Doeberitz, M.V. Reduction of β-catenin/T- cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003, 2: 509-16.
78. Dihlmann, S., Siermann, A., Doeberitz, M.V. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 2001, 20: 645-53.
79. Rice, P.L., Kelloff, J., Sullivan, H., Driggers, L.J., Beard, K.S., Kuwada, S., Piazza, G., Ahnen, D.J. Sulindac metabolites induce caspase- and proteasome-dependent degradation of β-catenin protein in human colon cancer cells. Mol Cancer Ther 2003, 2: 885-92.
80. Williams, J.L., Borgo, S., Hasan, I., Castillo, E., Traganos, F., Rigas, B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) after the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: Implications for colon cancer chemoprevention. Cancer Res 2001, 61: 3285-9.
81. Williams, J.L., Nath, N., Chen, J., Hundley, T.R., Gao, J., Kopelovich, L., Kashfi, K., Rigas, B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and β-catenin/T-cell factor signaling, nuclear factor-κB, and NO synthase 2 inhibition: Implications for chemoprevention. Cancer Res 2003, 63: 7613-8.
82. Nath, N., Kashfi, K., Chen, J., Rigas, B. Nitric oxide-donating aspirin inhibits beta-catenin T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear β-catenin-TCF association. Proc Natl Acad Sci USA 2003, 100: 12584-9.
83. Zhou, X.M., Wong, B.C.Y., Fan, X.M., Zhang, H.B., Lin, M.C.M., Kung, H.F., Fan, D.M., Lam, S.K. Non-steroidal anti-inflammatory drugs induce apoptosis in gastric cancer cells through up-regulation of bax and bak. Carcinogenesis 2001, 22: 1393-7.
84. Lim, J.T.E., Piazza, G.A., Han, E.K.H, Delohery, T.M., Li, H., Finn, T.S., Buttyan, R., Yamamoto, H., Sperl, G.J., Brendel, K., Gross, P.H., Pamukcu, R., Weinstein, I.B. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999, 58: 1097-107.
85. Liu, X.H., Yao, S., Kirschenbaum, A., Levine, A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998, 58: 4245-9.
86. Dormond, O., Ruegg, C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: Emerging mechanisms and therapeutic perspectives. Drug Resist Updates 2001, 4: 314-21.
87. Hsu, A.L., Ching, T.T., Wang, D.S., Song, X.Q., Rangnekar, V.M., Chen, C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275: 11397-403.
88. Berman, K.S., Verma, U.N., Harburg, G., Minna, J.D., Cobb, M.H., Gaynor, R.B. Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clin Cancer Res 2002, 8: 354-60.
89. Jones, M.K., Wang, H.T., Peskar, B.M., Levin, E., Itani, R.M., Sarfeh, I.J., Tarnawski, A.S. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999, 5: 1418-23.
90. Shureiqi, I., Jiang, W., Fischer, S.M., Xu, X.C., Chen, D.N., Lee, J.J., Lotan, R., Lippman, S.M. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res 2002, 62: 1178-83.
91. Shappell, S.B., Manning, S., Boeglin, W.E., Guan, Y.F., Roberts, R.L., Davis, L., Olson, S.J., Jack, G.S., Coffey, C.S., Wheeler, T.M., Breyer, M.D., Brash, A.R. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 2001, 3: 287-303.
92. Shureiqi, I., Chen, D., Lotan, R., Yang, P., Newman, R.A., Fischer, S.M., Lippman, S.M. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 2000, 60: 6846-50.
93. Shureiqi, I., Chen, D., Lee, J.J., Yang, P., Newman, R.A., Brenner, D.E., Lotan, R., Fischer, S.M., Lippman, S.M. 15-LOX-1: A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst 2000, 92: 1136-42.
94. Shureiqi, I., Xu, X., Chen, D., Lotan, R., Morris, J.S., Fischer, S.M., Lippman, S.M. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 2001, 61: 4879-84.
95. Xu, X.C., Shappell, S.B., Liang, Z., Song, S., Menter, D., Subbarayan, V., Iyengar, S., Tang, D.G., Lippman, S.M. Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 2003, 5: 121-7.
96. Wu, J., Xia, H.H., Tu, S.P., Fan, D.M., Lin, M.C., Kung, H.F., Lam, S.K., Wong, B.C. 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis. 2003, 24: 243-7
97. Shureiqi, I., Jiang, W., Zuo, X., Wu, Y., Stimmel, J.B., Leesnitzer, L.M., Morris, J.S., Fan, H.Z., Fischer, S.M, Lippman, S.M. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA 2003, 100: 9968-73.
98. Hao, C.M., Redha, R., Morrow, J., Breyer, M.D. Peroxisome proliferator-activated receptor δ activation promotes cell survival following hypertonic stress. J Biol Chem 2002, 277: 21341-5.
99. Glinghammar, B., Skogsberg, J., Hamsten, A., Ehrenborg, E. PPAR δ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Comm 2003, 308: 361-8.
100. Pan, Y.Q., Zhang, J.S., Gazi, M.H., Young, C.Y.F. The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomark Prevent 2003, 12: 769-74.
101. Zhu, W., Smith, A., Young, C.Y.F. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 1999, 140: 5451-4.
102. Brawer, M.K., Ellis, W.J. Chemoprevention forprostate cancer. Cancer 1995, 75: 1783-9.
103. Pienta, K., Esper, P. Risk factors for prostate cancer. Ann Intern Med 1993, 118: 793-803.
104. Kolonel, L.N., Nomura, A.M.Y., Cooney, R.V. Dietary fat and prostate cancer: Current status. J Natl Cancer Inst 1999, 91: 414-28.
105. Dorgan, J.F., Judd, J.T., Longcope, C., Brown, C., Schatzkin, A., Clevidence, B.A., Campbell, W.S., Nair, P.P., Franz, C., Kahle, L., Taylor, P.R. Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men - A controlled feeding study. Am J Clin Nutr 1996, 64: 850-5.
106. Hamalainen, E., Adlercreutz, H., Puska, P., Pietinen, P. Diet and serum sex hormones in healthy men. J Steroid Biochem 1984, 20: 459-64.
107. Gann, P.H., Hennekens, C.H., Ma, J., Longcope, C., Stampfer, M.J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88: 1118-26.
108. Lane, K.E., Leav, I., Ziar, J., Bridges, R.S., Rand, W.M., Ho, S.M. Suppression of testosterone and estradiol-17β-induced dysplasia in the dorsolateral prostate of Noble rats by bromoctiptine. Carcinogenesis 1997, 18: 1505-10.
109. Yaono, M., Tamano, S., Mori, T., Kato, K., Imaida, K., Asamoto, M., Shirai, T. Lobe specific effects of testosterone and estrogen on 3,2′-dimethyl-4-aminobiphenyl-induced rat prostate carcinogenesis. Cancer Lett 2000, 150: 33-40.
110. Lindzey, J., Kumar, M.V., Grossmann, M., Young, C.Y.F., Tindall, D.J. Molecular mechanisms of androgen action. Vitamin Horm 1994, 49: 383-432.
111. Thompson, L., Feigl, P., Coltman, C. Chemoprevetion of prostate cancer with finasteride. In: Important Advances in Oncology. V.T. DeVita, Jr., S. Hellman, S.A. Rosenberg (Eds.). J.B. Lippincott: Philadelphia, 1996, 57-76.
112. Simard, J., Dumont, M., Soucy, P., Labrie, F. Perspective: Prostate cancer susceptibility genes. Endocrinology 2002, 143: 2029-40.
113. Hayes, R.B. Gene-environment interrelations in prostate cancer. Epidemiol Rev 2001, 23: 163-7.
114. Lieberman, R., Bermejo, C., Akaza, H., Greenwald, P., Fair, W., Thompson, I. Progress in prostate cancer chemoprevention: Modulators of promotion and progression. Urology 2001, 58: 835-42.
115. Ripple, M.O., Henry, W.F., Schwarze, S.R., Wilding, G., Weindruch, R. Effect of antioxidants on androgen-induced AP-1 and NF-κB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1999, 91: 1227-32.
116. Fleshner, N.E., Klotz, L.H. Diet, androgens, oxidative stress and prostate cancer susceptibility. Cancer Metast Rev 1998, 17: 325-30.
117. Truica, C.I., Byers, S., Gelmann, E.P. β-Catenin affects androgen receptor transcriptional activity and ligand specificity Cancer Res 2000, 60: 4709-13.
118. Lu, M.L., Schneider, M.C., Zheng, Y.X., Zhang, X.B., Richie, J.P. Caveolin-1 interacts with androgen receptor - A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001, 276: 13442-51.
119. Gregory, C.W., He, B., Johnson, R.T., Ford, O.H., Mohler, J.L., French, F.S., Wilson, E.M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61: 4315-9.
120. Chesire, D.R., Isaacs, W.B. Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor. Oncogene 2002, 21: 8453-69.
121. Song, L.N., Herrell, R., Byers, S., Shah, S., Wilson, E.M., Gelmann, E.P. β-Catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003, 23: 1674-87.
122. Yang, F.J., Li, X.Y., Sharma, M., Sasaki, C.Y., Longo, D.L., Lim, B., Sun, Z.J. Linking β-catenin to androgen-signaling pathway. J Biol Chem 2002, 277: 11336-44.
123. Yamamoto, A., Hashimoto, Y., Kohri, K., Ogata, E., Kato, S., Ikeda, K., Nakanishi, M. Cyclin E as a coactivator of the androgen receptor. J Cell Biol 2000, 150: 873-9.
124. Hayes, S.A., Zarnegar, M., Sharma, M., Yang, F.J., Peehl, D.M., ten Dijke, P., Sun, Z.J. SMAD3 represses androgen receptor-mediated transcription. Cancer Res 2001, 61 (5): 2112-8.
125. Kang, H.Y., Huang, K.E., Chang, S.Y., Ma, W.L., Lin, W.J., Chang, C. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 2002, 277: 43749-56.
126. Poukka, H., Aarnisalo, P., Santti, H., Janne, O.A., Palvimo, J.J. Coregulator small nuclear RING finger protein (SNURF) enhances Sp1- and steroid receptor-mediated transcription by different mechanisms. J Biol Chem 2000, 275: 571-9.
127. Petre, C.E., Wetherill, Y.B., Danielsen, M., Knudsen, K.E. Cyclin D1: Mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 2002, 277: 2207-15.
128. Kotaja, N., Aittomaki, S., Silvennoinen, O., Palvimo, J.J., Janne, O.A. ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol Endocrinol 2000, 14: 1986-2000.
129. Liao, G.Q., Chen, L.Y, Zhang, A.H., Godavarthy, A., Xia, F., Ghosh, J.C., Li, H., Chen, J.D. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003, 278: 5052-61.
130. Irvine, R.A., Yu, M.C., Ross, R.K., Coetzee, G.A. The CAG and GCC micro-satellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55: 1937-40.
131. Hsing, A.W., Gao, Y.T., Wu, G., Wang, X., Deng, J., Chen, Y.L., Sesterhenn, I.A., Mostofi, F.K., Benichou, J., Chang, C.S. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res 2000, 60: 5111-6.
132. Platz, E.A., Rimm, E.B., Willett, W.C., Kantoff, P.W., Giovanucci, E. Racial variation in prostate cancer incidence and in the hormonal system markers among male health professionals. J Natl Cancer Inst 2000, 92: 2009-17.
133. Zha, S., Gage, W.R., Sauvageot, J., Saria, E.A., Putzi, M.J., Ewing, C.M., Faith, D.A., Nelson, W.G., De Marzo, A.M., Isaacs, W.B. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001, 61: 8617-23
134. Wagner, E.F. AP-1- Introductory remarks. Oncogene 2001, 20: 2334-5.
135. Hayes, J.D., McMahon, M. Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett 2001, 174: 103-13.
136. Kataoka, K., Shioda, S., Yoshitomo-Nakagawa, K., Handa, H., Nishizawa, M. Maf and Jun nuclear oncoproteins share downstream target genes for inducing cell transformation. J Biol Chem 2001, 276: 36849-56.
137. Lee, S.K., Kim, J.H., Lee, Y.C., Cheong, J.H., Lee, J.W. Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-κB, and serum response factor. J Biol Chem 2000, 275: 12470-4.
138. Rogatsky, I., Zarember, K.A., Yamamoto, K.R. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 2001, 20: 6071-83.
139. Suzukawa, K., Colburn, N.H. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers. Oncogene 2002, 21: 2181-90.
140. Pessah, M., Prunier, C., Marais, J., Ferrand, N., Mazars, A., Lallemand, F., Gauthier, J.M., Afti, A. c-Jun interacts with the corepressor TG-interacting factor (TGIF) to suppress Smad2 transcriptional activity. Proc Natl Acad Sci USA 2001, 98: 6198-203.
141. Sharma, M., Sun, Z. 5 'TG3' interacting factor interacts with Sin3A and represses AR-mediated transcription. Mol Endocrinol 2001, 15: 1918-28.
142. Shabsigh, A., Ghafar, M.A., de la Taille, A., Burchardt, M., Kaplan, S.A., Anastasiadis, A.G., Buttyan, R. Biomarkeranalysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001, 81: 437-44.
143. Feng, Z., Joos, H.J., Vallan, C., Muhlbauer, R., Altermatt, H.J., Jaggi, R. Apoptosis during castration-induced regression of the prostate is Fos dependent. Oncogene 1998, 17: 2593-600.
144. 2+ mobilization on expression of androgen-regulated genes: Interference with androgen receptor-mediated transactivation by AP-I proteins. Prostate 1997, 33: 264-70.
145. Chung, B.H., Mitchell, S.H., Zhang, J.S., Young, C.Y. Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. Carcinogenesis 2001, 22: 1201-6.
146. Yang-Yen, H.F., Chambard, J.C., Sun, Y.L., Smeal, T., Schmidt, T.J., Drouin, J., Karin, M. Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990, 62: 1205-15.
147. Schule, R., Rangarajan, P., Kliewer, S., Ransone, L.J., Bolado, J., Yang, N., Verma, I.M., Evans, R. M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 1990, 62: 1217-26.
148. Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta, H., Herrlich, P. Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990, 62: 1189-204.
149. Tzukerman, M., Zhang, X.K., Pfahl, M. Inhibition of estrogen receptor activity by the tumor promoter 12-O-tetradeconylphorbol-13-acetate: A molecular analysis. Mol Endocrinol 1991, 5: 1983-92.
150. Jorgensen, J.S., Nilson, J.H. AR suppresses transcription of the α glycoprotein hormone subunit gene through protein-protein interactions with cJun and activation transcription factor 2. Mol Endocrinol 2001, 15: 1496-504.
151. Wang, Q., Lu, J.H., Yong, E.L. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 2001, 276: 7493-9.
152. Aarnisalo, P., Palvimo, J.J., Janne, O.A. Creb-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 1998, 95: 2122-7.
153. Sato, N., Sadar, M.D., Bruchovsky, N., Saatcioglu, F., Rennie, P.S., Sato, S., Lange, P.H., Gleave, M E. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997, 272: 17485-94.
154. Fronsdal, K., Engedal, N., Slagsvold, T., Saatcioglu, F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 1998, 273: 31853-9.
155. Rigas, B., Shiff, S.J. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 2000, 54: 210-5.
156. Wechter, W.J., Leipold, D.D., Murray, E.D., Quiggle, D., McCracken, J.D., Barrios, R.S., Greenberg, N.M. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000, 60: 2203-8.
157. Wechter, W.J., Murray, E.D., Kantoci, D., Quiggle, D.D., Leipold, D.D., Gibson, K.M., McCracken, J.D. Treatment and survival study in the C57BL/6J-APC(Min)/+ (Min) mouse with R-flurbiprofen. Life Sci 2000, 66: 745-53.
158. Raz, A. Is inhibition of cyclooxygenase required for the antitumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002, 63: 343-7.